A Sanger Institute study identifies four categories of mutations contributing to drug resistance in colon, lung, and Ewing sarcoma cancers.
A study by the Wellcome Sanger Institute and collaborators has identified four categories of mutations that contribute to drug resistance in colon, lung, and Ewing sarcoma cancers. These include canonical drug resistance mutations, drug addiction mutations, driver mutations, and drug sensitizing variants. The findings, published in Nature Genetics, aim to guide personalized therapies and inform treatment strategies, potentially leading to more effective cancer treatments that circumvent resistance.
October 18, 2024
5 Articles